用于监管决策的药物计量学：现状与展望。 - Suppr

Pharmacometrics for regulatory decision making: status and perspective.

作者信息

Manolis Efthymios, Herold Ralf

机构信息

European Medicines Agency (EMA), London, UK.

出版信息

Clin Pharmacokinet. 2011 Oct;50(10):625-6. doi: 10.2165/11594340-000000000-00000.

DOI:10.2165/11594340-000000000-00000

PMID:21895035

Abstract

摘要

相似文献

Pharmacometrics for regulatory decision making: status and perspective.

Clin Pharmacokinet. 2011 Oct;50(10):625-6. doi: 10.2165/11594340-000000000-00000.

Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.

AAPS J. 2005 Oct 7;7(3):E503-12. doi: 10.1208/aapsj070351.

Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.

Clin Pharmacokinet. 2011 Oct;50(10):627-35. doi: 10.2165/11593210-000000000-00000.

Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.

Clin Pharmacol Ther. 2007 Feb;81(2):213-21. doi: 10.1038/sj.clpt.6100051.

Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.

J Clin Pharmacol. 2008 Feb;48(2):146-56. doi: 10.1177/0091270007311111.

Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, January-March 2019.

Am J Health Syst Pharm. 2019 Jun 18;76(13):e8-e9. doi: 10.1093/ajhp/zxz108.

Denouement: a patient-reported observation.

Value Health. 2007 Nov-Dec;10 Suppl 2:S146-7. doi: 10.1111/j.1524-4733.2007.00276.x.

New FDA breakthrough-drug category--implications for patients.

N Engl J Med. 2014 Mar 27;370(13):1252-8. doi: 10.1056/NEJMhle1311493.

The quantity and quality of worldwide new drug introductions, 1982-2003.

Health Aff (Millwood). 2006 Mar-Apr;25(2):452-60. doi: 10.1377/hlthaff.25.2.452.

Expiry date display on drug packages.

West J Med. 1996 Apr;164(4):365-6.

引用本文的文献

Editorial for the Special Issue "A Themed Issue in Honor of Professor Hartmut Derendorf-Outstanding Contributions in the Fields of Quantitative Clinical Pharmacology".

Antibiotics (Basel). 2023 Feb 8;12(2):353. doi: 10.3390/antibiotics12020353.

Model Informed Drug Development and Regulation in China: Challenges and Opportunities.

CPT Pharmacometrics Syst Pharmacol. 2019 Feb;8(2):59-61. doi: 10.1002/psp4.12368. Epub 2019 Jan 4.

Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.

Diabetes Technol Ther. 2015 Mar;17(3):215-23. doi: 10.1089/dia.2014.0222. Epub 2014 Dec 22.

Regulatory modeling and simulation moves into the next gear in europe.

CPT Pharmacometrics Syst Pharmacol. 2013 Feb 27;2(2):e32. doi: 10.1038/psp.2013.8.

The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop.

CPT Pharmacometrics Syst Pharmacol. 2013 Feb 27;2(2):e31. doi: 10.1038/psp.2013.7.

Modeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claims.

CPT Pharmacometrics Syst Pharmacol. 2013 Feb 27;2(2):e27. doi: 10.1038/psp.2013.4.

CPT: Pharmacometrics and Systems Pharmacology.

CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1(9):e8. doi: 10.1038/psp.2012.8.

Basic concepts in population modeling, simulation, and model-based drug development.

CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1(9):e6. doi: 10.1038/psp.2012.4.

Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.

Expert Rev Clin Pharmacol. 2013 Mar;6(2):159-70. doi: 10.1586/ecp.13.6.

Role of modelling and simulation: a European regulatory perspective.

Clin Pharmacokinet. 2012 Feb 1;51(2):69-76. doi: 10.2165/11596650-000000000-00000.

本文引用的文献

Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.

Clin Pharmacokinet. 2011 Oct;50(10):627-35. doi: 10.2165/11593210-000000000-00000.

Role of modeling and simulation in pediatric investigation plans.

Paediatr Anaesth. 2011 Mar;21(3):214-21. doi: 10.1111/j.1460-9592.2011.03523.x. Epub 2011 Jan 18.

Proposals for model-based paediatric medicinal development within the current European Union regulatory framework.

Br J Clin Pharmacol. 2009 Oct;68(4):493-501. doi: 10.1111/j.1365-2125.2009.03484.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Pharmacometrics for regulatory decision making: status and perspective.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Pharmacometrics for regulatory decision making: status and perspective.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献